Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ocrevus subcutaneous injection

Roche Basel Switzerland

Roche wins CHMP backing for Hemlibra

Haemophilia A treatment on course for European approval

Roche Basel Switzerland

Roche’s Ocrevus is first primary progressive MS drug in EU

Analysts predict the drug could be a $3bn product by 2021

Roche and GE Healthcare plan ‘industry first’ digital platform

Co-developed clinical decision support software will begin with cancer and critical care

Roche Basel Switzerland

Roche buys cancer company Ignyta for $1.7bn

Pursues same oncology target that encouraged Bayer's recent deal with Loxo

Novartis day

Novartis’ Extavia evades NICE restrictions on MS drugs

But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down

- PMLiVE

Roche preps kidney cancer filing for Tecentriq/Avastin combo

Says treatment reduced risk of disease worsening compared to Sutent

Roche preps kidney cancer filing for Tecentriq/Avastin combo

Says treatment reduced risk of disease worsening compared to Sutent

- PMLiVE

Data backs up Roche’s Tecentriq/Avastin combo in lung cancer

Results will be used to pursue a first-line indication in NSCLC

- PMLiVE

Mylan gets first biosimilar Herceptin OK from FDA

Ogivri approved by US regulators for all of Roche blockbuster's indications

- PMLiVE

Roche offers diabetes digital health programme to UK patients

Partners with OurPath for its six-week lifestyle management programme

- PMLiVE

First Herceptin biosimilar cleared in Europe

Ontruzant is approved for all the same indications as Roche’s blockbuster

- PMLiVE

Lung cancer data gives Roche’s Tecentriq a boost

Will help its PD-L1 inhibitor compete with Merck & Co’s Keytruda

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links